RNA å»è¬åäŒç€Ÿã§ãã Arcturus Therapeutics Holdings Inc. ã¯ãèèããã³åŒåžåšçŸæ£ã®æ²»çã«éç¹ã眮ããŠããŸããå瀟ã®åèšåºå»è¬åçºèŠããã³éçºããã°ã©ã ã«ã¯ããªã«ããã³ãã©ã³ã¹ã«ã«ããã©ãŒãŒ (OTC) æ¬ ä¹çã®ããã® LUNAR-OTC éçºããã°ã©ã ãå¢èæ§ç·ç¶çèã³ã³ãã¯ã¿ã³ã¹å¶åŸ¡å å (CFTR) éºäŒåã®å€ç°ã«ãã£ãŠåŒãèµ·ããããå¢èæ§ç·ç¶çæ§èºçŸæ£ã®ããã® LUNAR-CF ããã°ã©ã ããããŸããå瀟ã¯ãç±³åœããã³ãã®ä»ã®åœã§çºè¡ããã 209 ä»¶ã®ç¹èš±ããã³ç¹èš±åºé¡ã®ç¹èš±ããŒããã©ãªãªã§ã«ããŒãããŠãã LUNAR ããã³æ žé
žæè¡ãææããŠããŸããå瀟ã¯ãç¹å®ã®åžå°çŸæ£ãæšçãšãã mRNA æ²»çåè£ã®éçºã§ Ultragenyx Pharmaceutical, Inc. ãšãéã¢ã«ã³ãŒã«æ§èèªèçã®æ²»çãç®çãšããæ žé
žããŒã¹ã®æ²»çåè£ã®éçºã§ Millennium Pharmaceuticals, Inc. (æŠç°è¬å) ãšãB åèçãŠã€ã«ã¹ææçã®æ²»çãç®çãšããæ žé
žããŒã¹ã®æ²»çåè£ã®éçºã§ Janssen Pharmaceuticals, Inc. ãšååé¢ä¿ãçµãã§ããŸãã CureVac AG ã mRNA æ²»çè¬ããã³ã¯ã¯ãã³åè£ãéçºãã·ã³ã¬ããŒã«çµæžéçºåºãšãã¥ãŒã¯-NUS ã¡ãã£ã«ã« ã¹ã¯ãŒã«ã LUNAR-COV19 ã¯ã¯ãã³ãéçºãArcturus Therapeutics Holdings Inc. 㯠2013 幎ã«èšç«ãããã«ãªãã©ã«ãã¢å·ãµã³ãã£ãšãŽã«æ¬ç€Ÿã眮ããŠããŸãã